Results 141 to 150 of about 20,100 (304)

Thrombotic microangiopathy after kidney transplantation successfully treated with eculizumab: A case report

Transplantation Reports, 2018
Background: Transplantation-associated thrombotic microangiopathy (TA-TMA) is relatively rare and may cause graft failure. Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation of the alternative complement pathway, resulting in TMA ...
Tomoko Kawanishi, Jumpei Hasegawa, Momoko Kono, Ayumi Ishiwatari, Toshie Ogawa, Yasutomo Abe, Mariko Endo, Hidetoshi Ishigooka, Masayoshi Okumi, Kazunari Tanabe, Sachiko Wakai, Hiroki Shirakawa   +11 more
doaj  

Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report

Frontiers in Pediatrics
Eculizumab, a recombined humanized monoclonal antibody which possesses high affinity for the complement protein C5, is a therapeutic agent utilized in the treatment of atypical hemolytic uremic syndrome (aHUS) by inhibiting the terminal complement ...
Xin Wei, Xinzhu Liu, Yingying Yu, Wei Xie, Wentao Luo, Ye Tu, Shuhong Bu, Guimei Guo   +7 more
doaj   +1 more source

Eculizumab for Congenital Atypical Hemolytic–Uremic Syndrome [PDF]

, 2009
Ralph A. Gruppo, Russell P. Rother
openalex   +1 more source

Eculizumab in Early-Stage Pregnancy [PDF]

Kidney International Reports, 2020
Ignacio Herraiz, Manuel Praga, Enrique Morales, Marina Alonso, María Esther Rodríguez-Almaraz, Cecilia Villalain, Alberto Galindo, Eduardo Gutiérrez, Leticia García   +8 more
openaire   +3 more sources

Eculizumab for Atypical Hemolytic–Uremic Syndrome [PDF]

, 2009

openalex   +1 more source

The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab [PDF]

, 2010
Richard Kelly, Louise Arnold, Stephen J. Richards, Anita Hill, Charlotte Bomken, John Hanley, Andrew Loughney, Jon Beauchamp, Gus Khursigara, Russell P. Rother, Elizabeth Chalmers, Andrew Fyfe, Edward J. Fitzsimons, Ryotaro Nakamura, Anna Gayà, Antonio M. Risitano, Jörg Schubert, D. R. Norfolk, Nigel Simpson, Peter Hillmen   +19 more
openalex   +1 more source

Monoclonal IgG4/2κ Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation

Kidney Medicine, 2019
Eculizumab is an emerging therapy for atypical hemolytic uremic syndrome (aHUS). Early identification and treatment of recurrent aHUS after kidney transplantation requires a high clinical suspicion but results in improved graft function and patient ...
Priyamvada Singh, Hui Chen, Craig E. Gordon, Sandeep Ghai, J. Mark Sloan, Karen Quillen, Sara Moradi, Vipul Chitalia, Amitabh Gautam, Joel Henderson, Jean M. Francis   +10 more
doaj  

A Case of Hemolytic Uremic Syndrome in a 10-Year-Old Male With Severe Neurologic Involvement Successfully Treated With Eculizumab

Journal of Investigative Medicine High Impact Case Reports, 2017
Hemolytic uremic syndrome (HUS) can be classified as typical and atypical, and the treatment recommendations currently differ between the 2 types. Eculizumab is recommended as first-line treatment for atypical HUS; however, its use in typical HUS has ...
Malia Rasa MD, James Musgrave MD, Keith Abe MD, Len Tanaka MD, Konstantine Xoinis MD, Bruce Shiramizu MD, Gretchen Foskett MD, Rhiana Lau MD   +7 more
doaj   +1 more source

EFFECT OF TERMINAL COMPLEMENT INHIBITION BY ECULIZUMAB ON T-CELL AND NATURAL KILLER CELL DEPLETION IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS INDUCED WITH POLYCLONAL RABBIT ANTITHYMOCYTE GLOBULIN. [PDF]

, 2010
Brian K. P. Goh, Patrick G. Dean, Suresh Raghavaiah, Mark D. Stegall   +3 more
openalex   +1 more source

Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

EClinicalMedicine, 2020
Background: Complement pathway inhibition may provide benefit for severe acute respiratory illnesses caused by viral infections such as COVID-19. We present results from a nonrandomized proof-of-concept study of complement C5 inhibitor eculizumab for ...
Djillali Annane, Nicholas Heming, Lamiae Grimaldi-Bensouda, Véronique Frémeaux-Bacchi, Marie Vigan, Anne-Laure Roux, Armance Marchal, Hugues Michelon, Martin Rottman, Pierre Moine   +9 more
doaj